Cardinal Health (NYSE:CAH – Get Free Report) had its price target upped by equities researchers at Wells Fargo & Company from ...

Jefferies has upgraded Cardinal Health (CAH) to buy from hold, citing management's emerging EPS track record. Read more here.

With a positive outlook, McKesson raised its fiscal 2025 adjusted EPS guidance to a range of $32.55 to $32.95, indicating ...

Shares of Cardinal Health Inc. CAH advanced 1.82% to $127.45 Wednesday, on what proved to be an all-around great trading ...

Cencora simplifies distribution logistics by shipping products to centralized wholesaler locations, as opposed to shipping directly to pharmacies and various customer locations. Additionally, Cencora ...

Fintel reports that on February 5, 2025, Jefferies upgraded their outlook for Cardinal Health (NYSE:CAH) from Hold to Buy.

Drug distributor Cencora raised its fiscal 2025 profit forecast on Wednesday, driven by robust demand for expensive specialty medicines.

Several prospects are on the rise and the Cardinals are about to find out which ones are ready for the big-league fire.

Jefferies analyst Brian Tanquilut upgraded Cardinal Health (CAH) to Buy from Hold with a price target of $150, up from $140. The firm thinks ...

Swimming World explores bold ideas for transforming swimming - including NCAA - into a year-round spectacle beyond the ...

A survey found they think full implementation of new taxes on medical supplies coming in from Canada, China and Mexico could ...

Wells Fargo analyst Stephen Baxter maintained Cardinal Health with an Equal-Weight and raised the price target from $135 to ...